La Puente, California Clinical Trials

A listing of La Puente, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).

City of Hope National Medical Center
 (8.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +29 other locations
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

dulaglutide
cardiovascular disease
tirzepatide
body mass index
Valley Clinical Trials, Inc.
 (5.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +650 other locations
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168

Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary Objective: To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance …

pregnancy test urine
serum pregnancy test
urine test
contraceptive use
teriflunomide
Investigational Site Number 8400070
 (7.9 away) Contact site
  • 0 views
  • 09 Sep, 2025
  • +24 other locations
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute bioavailability of SC and IV isatuximab To measure receptor occupancy (RO) after isatuximab SC versus IV administration To assess …

hbv dna
contraceptive use
premedication
hepatitis a
pomalidomide
Investigational Site Number 8400002
 (9.5 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +13 other locations
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT …

medical castration
metastatic prostate cancer
atezolizumab
darolutamide
testosterone
Exelixis Clinical Site #2
 (8.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MPP2+ Recurrent or Progressive Glioblastoma

This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Vaccines made from a gene-modified virus may …

serum pregnancy test
glioma
expression by immunohistochemistry
absolute neutrophil count
neutrophil count
City of Hope Medical Center
 (8.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

testosterone
glomerular filtration rate
antiandrogen therapy
growth factor
serum testosterone
Research Site
 (8.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +3 other locations
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.

metastatic disease
metastatic castration-resistant prostate cancer
metastatic cancer
metastatic hormone refractory prostate cancer
castration-resistant prostate cancer
City of Hope Comprehensive Cancer Center
 (8.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +2 other locations
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the relapse rate but has some fatal side effects such as irreversible damage to normal internal …

bone marrow procedure
cell transplantation
ejection fraction
stem cell transplantation
ribonucleic acid
City of Hope Medical Center
 (8.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

pd-l1
erbb1
drug test
solid tumor
growth factor
Icri /Id# 217071
 (5.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations